Spinal muscular atrophy: Where are we now? Current challenges and high hopes

[1] Bebee TW, Dominguez CE, Chandler DS. Mouse models of SMA: Tools for disease characterization and therapeutic development. Hum Genet. 2012; 131: 1277–1293. BebeeTW DominguezCE ChandlerDS Mouse models of SMA: Tools for disease characterization and therapeutic development Hum Genet. 2012 131 1277 1293 10.1007/s00439-012-1171-522543872 Search in Google Scholar

[2] Willis TA. Therapeutic advances in spinal muscular atrophy. Paediatr Child Heal (United Kingdom). 2019; 29: 463–467. WillisTA Therapeutic advances in spinal muscular atrophy Paediatr Child Heal (United Kingdom). 2019 29 463 467 10.1016/j.paed.2019.07.009 Search in Google Scholar

[3] Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021; 16: 47. DangouloffT BottyC BeaudartC ServaisL HiligsmannM Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments Orphanet J Rare Dis. 2021 16 47 10.1186/s13023-021-01695-7782491733485382 Search in Google Scholar

[4] Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AHM, McPherson JD. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol Genet. 1999; 8: 1177–1183. MonaniUR LorsonCL ParsonsDW PriorTW AndrophyEJ BurghesAHM McPhersonJD A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2 Hum. Mol Genet. 1999 8 1177 1183 10.1093/hmg/8.7.117710369862 Search in Google Scholar

[5] Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020; 7: 1–13. SchorlingDC PechmannA KirschnerJ Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care J Neuromuscul Dis. 2020 7 1 13 10.3233/JND-190424702931931707373 Search in Google Scholar

[6] Tisdale S, Pellizzoni L. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci. 2015; 35: 8691–8700. TisdaleS PellizzoniL Disease mechanisms and therapeutic approaches in spinal muscular atrophy J Neurosci. 2015 35 8691 8700 10.1523/JNEUROSCI.0417-15.2015446168226063904 Search in Google Scholar

[7] Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002; 70: 358–368. FeldkötterM SchwarzerV WirthR WienkerTF WirthB Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy Am J Hum Genet. 2002 70 358 368 10.1086/33862741998711791208 Search in Google Scholar

[8] Bebee TW, Gladman JT, Chandler DS. Splicing of the survival motor neuron genes and implications for treatment of SMA. Front Biosci. 2010; 15: 1191–1204. BebeeTW GladmanJT ChandlerDS Splicing of the survival motor neuron genes and implications for treatment of SMA Front Biosci. 2010 15 1191 1204 10.2741/3670292169620515750 Search in Google Scholar

[9] Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN. Nat Genet. 2002; 30: 377–384. CartegniL KrainerAR Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN Nat Genet. 2002 30 377 384 10.1038/ng85411925564 Search in Google Scholar

[10] Russman BS. Spinal muscular atrophy: Clinical classification and disease heterogeneity. J Child Neurol. 2007; 22: 946–951. RussmanBS Spinal muscular atrophy: Clinical classification and disease heterogeneity J Child Neurol. 2007 22 946 951 10.1177/088307380730567317761648 Search in Google Scholar

[11] Maretina MA, Zheleznyakova GY, Lanko KM, Egorova AA, Baranov VS, Kiselev AV. Molecular factors involved in spinal muscular atrophy pathways as possible disease-modifying candidates. Curr Genomics. 2018; 19: 339–355. MaretinaMA ZheleznyakovaGY LankoKM EgorovaAA BaranovVS KiselevAV Molecular factors involved in spinal muscular atrophy pathways as possible disease-modifying candidates Curr Genomics. 2018 19 339 355 10.2174/1389202919666180101154916603085930065610 Search in Google Scholar

[12] Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: Progress and challenges. Neurotherapeutics. 2015; 12: 290–302. FarrarMA KiernanMC The genetics of spinal muscular atrophy: Progress and challenges Neurotherapeutics. 2015 12 290 302 10.1007/s13311-014-0314-x440444125413156 Search in Google Scholar

[13] Khorkova O, Wahlestedt C. Oligonucleotide therapies for disorders of the nervous system. Nat Biotechnol. 2017; 35: 249–263. KhorkovaO WahlestedtC Oligonucleotide therapies for disorders of the nervous system Nat Biotechnol. 2017 35 249 263 10.1038/nbt.3784604390028244991 Search in Google Scholar

[14] Li Q. Nusinersen as a therapeutic agent for spinal muscular atrophy. Yonsei Med J. 2020; 61: 273–283. LiQ Nusinersen as a therapeutic agent for spinal muscular atrophy Yonsei Med J. 2020 61 273 283 10.3349/ymj.2020.61.4.273710540732233169 Search in Google Scholar

[15] Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM. Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy. Neurology, 2016; 86: 890–897. ChiribogaCA SwobodaKJ DarrasBT IannacconeST MontesJ De VivoDC NorrisDA BennettCF BishopKM Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy Neurology 2016 86 890 897 10.1212/WNL.0000000000002445478211126865511 Search in Google Scholar

[16] Goodkey K, Aslesh T, Maruyama R, Yokota T. Nusinersen in the treatment of spinal muscular atrophy. Methods Mol Biol. 2018; 1828: 69–76. GoodkeyK AsleshT MaruyamaR YokotaT Nusinersen in the treatment of spinal muscular atrophy Methods Mol Biol. 2018 1828 69 76 10.1007/978-1-4939-8651-4_430171535 Search in Google Scholar

[17] Hoy SM. Nusinersen: First global approval. Drugs, 2017; 77: 473–479. HoySM Nusinersen: First global approval Drugs 2017 77 473 479 10.1007/s40265-017-0711-728229309 Search in Google Scholar

[18] Ramdas S, Servais L. New treatments in spinal muscular atrophy: An overview of currently available data. Expert Opin Pharmacother. 2020; 21: 307–315. RamdasS ServaisL New treatments in spinal muscular atrophy: An overview of currently available data Expert Opin Pharmacother. 2020 21 307 315 10.1080/14656566.2019.170473231973611 Search in Google Scholar

[19] Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study. Lancet, 2016; 388: 3017–3026. FinkelRS ChiribogaCA VajsarJ DayJW MontesJ De VivoDC YamashitaM RigoF HungG SchneiderE Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study Lancet 2016 388 3017 3026 10.1016/S0140-6736(16)31408-827939059 Search in Google Scholar

[20] De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, Kirschner J, Kuntz NL, Parsons JA, Ryan MM, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019; 29: 842–856. De VivoDC BertiniE SwobodaKJ HwuWL CrawfordTO FinkelRS KirschnerJ KuntzNL ParsonsJA RyanMM Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study Neuromuscul Disord. 2019 29 842 856 10.1016/j.nmd.2019.09.007712728631704158 Search in Google Scholar

[21] Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018; 378: 625–635. MercuriE DarrasBT ChiribogaCA DayJW CampbellC ConnollyAM IannacconeST KirschnerJ KuntzNL SaitoK Nusinersen versus Sham control in later-onset spinal muscular atrophy N Engl J Med. 2018 378 625 635 10.1056/NEJMoa171050429443664 Search in Google Scholar

[22] AveXis Inc. ZOLGENSMA® US product information 2019 [https://www.fda.gov/vaccines-blood-biologics/zolgensma] accessed 09.02.2021. AveXis Inc. ZOLGENSMA® US product information 2019 [https://www.fda.gov/vaccines-blood-biologics/zolgensma] accessed 09.02.2021. Search in Google Scholar

[23] National Institute for Health Research. AVXS-101 for spinal muscular atrophy. 2018 [http://www.io.nihr.ac.uk/report/avxs-101-for-spinal-muscular-atrophy/] accessed 09.02.2021. National Institute for Health Research AVXS-101 for spinal muscular atrophy 2018 [http://www.io.nihr.ac.uk/report/avxs-101-for-spinal-muscular-atrophy/] accessed 09.02.2021. Search in Google Scholar

[24] Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017; 377: 1713–1722. MendellJR Al-ZaidyS ShellR ArnoldWD Rodino-KlapacLR PriorTW LowesL AlfanoL BerryK ChurchK Single-dose gene-replacement therapy for spinal muscular atrophy N Engl J Med. 2017 377 1713 1722 10.1056/NEJMoa170619829091557 Search in Google Scholar

[25] Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Dabbous O. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Heal Policy, 2019; 7: 1601484. MaloneDC DeanR ArjunjiR JensenI CyrP MillerB MaruB SprouleDM FeltnerDE DabbousO Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients J Mark Access Heal Policy 2019 7 1601484 10.1080/20016689.2019.1601484650805831105909 Search in Google Scholar

[26] Roche. Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) 2020 [media release] [https://www.roche.com/media/releases/med-cor-2020-06-12.htm] accessed 20.02.2021. Roche Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) 2020 [media release] [https://www.roche.com/media/releases/med-cor-2020-06-12.htm] accessed 20.02.2021. Search in Google Scholar

[27] Drug Trials Snapshots: EVRYSDI. US product information. 2020 [https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-evrysdi] accessed 20.02.2021. Drug Trials Snapshots: EVRYSDI US product information 2020 [https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-evrysdi] accessed 20.02.2021. Search in Google Scholar

[28] Servais L, Baranello G, Day JW, Deconinck N, Mercuri E, Klein A, Darras B, Masson R, Kletzl H, Cleary Y, et al. FIREFISH Part 1: Survival, ventilation and swallowing ability in infants with Type 1 SMA receiving risdiplam (RG7916). 2019. ServaisL BaranelloG DayJW DeconinckN MercuriE KleinA DarrasB MassonR KletzlH ClearyY FIREFISH Part 1: Survival, ventilation and swallowing ability in infants with Type 1 SMA receiving risdiplam (RG7916) 2019 Search in Google Scholar

[29] Servais L, Baranello G, Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Vlodavets D, Xiong H, Zanoteli E, El-Khairi M, Fuerst-Recktenwald S, et al. FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA). ServaisL BaranelloG MassonR Mazurkiewicz-BełdzińskaM RoseK VlodavetsD XiongH ZanoteliE El-KhairiM Fuerst-RecktenwaldS FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA) Search in Google Scholar

[30] Dhillon S. Risdiplam: First approval. Drugs, 2020; 80: 1853–1858. DhillonS Risdiplam: First approval Drugs 2020 80 1853 1858 10.1007/s40265-020-01410-z33044711 Search in Google Scholar

[31] Chiriboga CA, Bruno C, Duong T, Fischer D, Kirschner J, Mercuri E, Carruthers I, Gerber M, Gorni K, Kletzl H, et al. JEWELFISH: Safety and pharmacodynamic data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam. ChiribogaCA BrunoC DuongT FischerD KirschnerJ MercuriE CarruthersI GerberM GorniK KletzlH JEWELFISH: Safety and pharmacodynamic data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam Search in Google Scholar

[32] Cheung AK, Hurley B, Kerrigan R, Shu L, Chin DN, Shen Y, O'Brien G, Sung MJ, Hou Y, Axford J, et al. Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018; 61: 11021–11036. CheungAK HurleyB KerriganR ShuL ChinDN ShenY O'BrienG SungMJ HouY AxfordJ Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SMA) J Med Chem. 2018 61 11021 11036 10.1021/acs.jmedchem.8b0129130407821 Search in Google Scholar

[33] Palacino J, Swalley SE, Song C, Cheung AK, Shu L, Zhang X, Van Hoosear M, Shin Y, Chin DN, Keller CG, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. 2015; 11: 511–517. PalacinoJ SwalleySE SongC CheungAK ShuL ZhangX Van HoosearM ShinY ChinDN KellerCG SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice Nat Chem Biol. 2015 11 511 517 10.1038/nchembio.183726030728 Search in Google Scholar

[34] Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, Godinez G, Lee KH, Marquez D, Browne IV WF, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012; 18: 452–455. RussellAJ HartmanJJ HinkenAC MuciAR KawasR DriscollL GodinezG LeeKH MarquezD BrowneWFIV Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases Nat Med. 2012 18 452 455 10.1038/nm.2618329682522344294 Search in Google Scholar

[35] Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve, 2018; 57: 729–734. AndrewsJA MillerTM VijayakumarV StoltzR JamesJK MengL WolffAA MalikFI CK-2127107 amplifies skeletal muscle response to nerve activation in humans Muscle Nerve 2018 57 729 734 10.1002/mus.26017668106529150952 Search in Google Scholar

[36] Pirruccello-Straub M, Jackson J, Wawersik S, Webster MT, Salta L, Long K, McConaughy W, Capili A, Boston C, Carven GJ, et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci Rep. 2018; 8: 2292. Pirruccello-StraubM JacksonJ WawersikS WebsterMT SaltaL LongK McConaughyW CapiliA BostonC CarvenGJ Blocking extracellular activation of myostatin as a strategy for treating muscle wasting Sci Rep. 2018 8 2292 10.1038/s41598-018-20524-9579720729396542 Search in Google Scholar

[37] Dagbay KB, Treece E, Streich FC, Jackson JW, Faucette RR, Nikiforov A, Lin SC, Boston CJ, Nicholls SB, Capili AD, Carven GJ. Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015. J Biol Chem. 2020; 295: 5404–5418. DagbayKB TreeceE StreichFC JacksonJW FaucetteRR NikiforovA LinSC BostonCJ NichollsSB CapiliAD CarvenGJ Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015 J Biol Chem. 2020 295 5404 5418 10.1074/jbc.RA119.012293717053232075906 Search in Google Scholar

[38] Long KK, O'Shea KM, Khairallah RJ, Howell K, Paushkin S, Chen KS, Cote SM, Webster MT, Stains JP, Treece E, et al. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet. 2019; 28: 1076–1089. LongKK O'SheaKM KhairallahRJ HowellK PaushkinS ChenKS CoteSM WebsterMT StainsJP TreeceE Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy Hum Mol Genet. 2019 28 1076 1089 10.1093/hmg/ddy382642342030481286 Search in Google Scholar

[39] Xiao WH, Zheng FY, Bennett GJ, Bordet T, Pruss RM. Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain, 2009; 147: 202–209. XiaoWH ZhengFY BennettGJ BordetT PrussRM Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel Pain 2009 147 202 209 10.1016/j.pain.2009.09.006278791019833436 Search in Google Scholar

[40] Muntoni F, Bertini E, Comi G, Kirschner J, Lusakowska A, Mercuri E, Scoto M, van der Pol WL, Vuillerot C, Burdeska A, et al. Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscul Disord. 2020; 30: 959–969. MuntoniF BertiniE ComiG KirschnerJ LusakowskaA MercuriE ScotoM van der PolWL VuillerotC BurdeskaA Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial Neuromuscul Disord. 2020 30 959 969 10.1016/j.nmd.2020.10.00833246887 Search in Google Scholar

[41] Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017; 16: 513–522. BertiniE DessaudE MercuriE MuntoniF KirschnerJ ReidC LusakowskaA ComiGP CuissetJM AbitbolJL Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: A randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol. 2017 16 513 522 10.1016/S1474-4422(17)30085-628460889 Search in Google Scholar

[42] Ratni H, Karp GM, Weetall M, Naryshkin NA, Paushkin SV, Chen KS, McCarthy KD, Qi H, Turpoff A, Woll MG, et al. Specific correction of alternative survival motor neuron 2 splicing by small molecules: Discovery of a potential novel medicine to treat spinal muscular atrophy. J Med Chem, 2016; 59: 6086–6100. RatniH KarpGM WeetallM NaryshkinNA PaushkinSV ChenKS McCarthyKD QiH TurpoffA WollMG Specific correction of alternative survival motor neuron 2 splicing by small molecules: Discovery of a potential novel medicine to treat spinal muscular atrophy J Med Chem 2016 59 6086 6100 10.1021/acs.jmedchem.6b0045927299419 Search in Google Scholar

[43] Kletzl H, Marquet A, Günther A, Tang W, Heuberger J, Groeneveld GJ, Birkhoff W, Mercuri E, Lochmüller H, Wood C, et al. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy. Neuromuscul Disord. 2019; 29: 21–29. KletzlH MarquetA GüntherA TangW HeubergerJ GroeneveldGJ BirkhoffW MercuriE LochmüllerH WoodC The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy Neuromuscul Disord. 2019 29 21 29 10.1016/j.nmd.2018.10.00130553700 Search in Google Scholar

[44] Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, Denk N, Feng Z, Green L, Guerard M, et al. Discovery of Risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018; 61: 6501–6517. RatniH EbelingM BairdJ BendelsS BylundJ ChenKS DenkN FengZ GreenL GuerardM Discovery of Risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA) J Med Chem. 2018 61 6501 6517 10.1021/acs.jmedchem.8b0074130044619 Search in Google Scholar

[45] Van Meerbeke JP, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin MY, Rucki AA, Wee CD, Xia B, Sharma S, et al. The DcpS inhibitor RG3039 improves motor functionin SMA mice. Hum Mol Genet. 2013; 22: 4074–4083. Van MeerbekeJP GibbsRM PlastererHL MiaoW FengZ LinMY RuckiAA WeeCD XiaB SharmaS The DcpS inhibitor RG3039 improves motor functionin SMA mice Hum Mol Genet. 2013 22 4074 4083 10.1093/hmg/ddt257378163723727836 Search in Google Scholar

[46] Gogliotti RG, Cardona H, Jasbir S, Bail S, Emery C, Kuntz N, Jorgensen M, Durens Madel M, Xia B, Barlow C, et al. The dcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet. 2013; 22: 4084–4101. GogliottiRG CardonaH JasbirS BailS EmeryC KuntzN JorgensenM Durens MadelM XiaB BarlowC The dcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models Hum Mol Genet. 2013 22 4084 4101 10.1093/hmg/ddt258378163823736298 Search in Google Scholar

[47] Mohseni J, Zabidi-Hussin ZAMH, Sasongko TH. Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy. Genet Mol Biol. 2013; 36: 299–307. MohseniJ Zabidi-HussinZAMH SasongkoTH Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy Genet Mol Biol. 2013 36 299 307 10.1590/S1415-47572013000300001379517324130434 Search in Google Scholar

[48] Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, Wood J, Acsadi G, Crawford TO, Kissel JT, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One, 2009; 4: e5268. SwobodaKJ ScottCB ReynaSP PriorTW LaSalleB SorensonSL WoodJ AcsadiG CrawfordTO KisselJT Phase II open label study of valproic acid in spinal muscular atrophy PLoS One 2009 4 e5268 10.1371/journal.pone.0005268268003419440247 Search in Google Scholar

[49] Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, et al. SMA CARNI-VAL trial part I: Double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One, 2010; 5: e12140. SwobodaKJ ScottCB CrawfordTO SimardLR ReynaSP KrosschellKJ AcsadiG ElsheikB SchrothMK D'AnjouG SMA CARNI-VAL trial part I: Double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy PLoS One 2010 5 e12140 10.1371/journal.pone.0012140292437620808854 Search in Google Scholar

[50] Kissel JT, Scott CB, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, et al. SMA CARNI-VAL TRIAL PART II: A prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One, 2011; 6: e21296. KisselJT ScottCB ReynaSP CrawfordTO SimardLR KrosschellKJ AcsadiG ElsheikB SchrothMK D'AnjouG SMA CARNI-VAL TRIAL PART II: A prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy PLoS One 2011 6 e21296 10.1371/journal.pone.0021296313073021754985 Search in Google Scholar

[51] Kissel JT, Elsheikh B, King WM, Freimer M, Scott CB, Kolb SJ, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, et al. SMA valiant trial: A prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve. 2014; 49: 187–192. KisselJT ElsheikhB KingWM FreimerM ScottCB KolbSJ ReynaSP CrawfordTO SimardLR KrosschellKJ SMA valiant trial: A prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy Muscle Nerve. 2014 49 187 192 10.1002/mus.23904388883323681940 Search in Google Scholar

[52] Ojala KS, Reedich EJ, DiDonato CJ. Meriney SD. In search of a cure: The development of therapeutics to alter the progression of spinal muscular atrophy. Brain Sci. 2021; 11: 194. OjalaKS ReedichEJ DiDonatoCJ MerineySD In search of a cure: The development of therapeutics to alter the progression of spinal muscular atrophy Brain Sci. 2021 11 194 10.3390/brainsci11020194791583233562482 Search in Google Scholar

[53] Hjorth E, Kreicbergs U, Sejersen T, Lövgren M. Parents' advice to healthcare professionals working with children who have spinal muscular atrophy. Eur J Paediatr Neurol. 2018; 22: 128–134. HjorthE KreicbergsU SejersenT LövgrenM Parents' advice to healthcare professionals working with children who have spinal muscular atrophy Eur J Paediatr Neurol. 2018 22 128 134 10.1016/j.ejpn.2017.10.00829146237 Search in Google Scholar

[54] López-Bastida J, Peña-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017; 12: 141. López-BastidaJ Peña-LongobardoLM Aranda-ReneoI TizzanoE SeftonM Oliva-MorenoJ Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain Orphanet J Rare Dis. 2017 12 141 10.1186/s13023-017-0695-0556303528821278 Search in Google Scholar

[55] Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: A qualitative study. BMC Neurol., 2015; 15: 217. QianY McGrawS HenneJ JareckiJ HobbyK YehWS Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: A qualitative study BMC Neurol. 2015 15 217 10.1186/s12883-015-0473-3461951326499462 Search in Google Scholar

[56] Tejero R, Balk S, Franco-Espin J, Ojeda J, Hennlein L, Drexl H, Dombert B, Clausen JD, Torres-Benito L, Saal-Bauernschubert L, et al. R-Roscovitine improves motoneuron function in mouse models for spinal muscular atrophy. iScience, 2020; 23: 100826. TejeroR BalkS Franco-EspinJ OjedaJ HennleinL DrexlH DombertB ClausenJD Torres-BenitoL Saal-BauernschubertL R-Roscovitine improves motoneuron function in mouse models for spinal muscular atrophy iScience 2020 23 100826 10.1016/j.isci.2020.100826699299631981925 Search in Google Scholar

[57] Sansone VA, Pirola A, Albamonte E, Pane M, Lizio A, D'Amico A, Catteruccia M, Cutrera R, Bruno C, Pedemonte M, et al. Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen. J Pediatr. 2020; 219: 223–228.e4. SansoneVA PirolaA AlbamonteE PaneM LizioA D'AmicoA CatterucciaM CutreraR BrunoC PedemonteM Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen J Pediatr. 2020 219 223 228.e4 10.1016/j.jpeds.2019.12.04732035635 Search in Google Scholar

[58] Cruz R, Belter L, Wasnock M, Nazarelli A, Jarecki J. Evaluating benefit-risk decision-making in spinal muscular atrophy: A first-ever study to assess risk tolerance in the SMA patient community. Clin Ther. 2019; 41: 943–960.e4. CruzR BelterL WasnockM NazarelliA JareckiJ Evaluating benefit-risk decision-making in spinal muscular atrophy: A first-ever study to assess risk tolerance in the SMA patient community Clin Ther. 2019 41 943 960.e4 10.1016/j.clinthera.2019.03.01231056304 Search in Google Scholar